Japanese Encephalitis Virus Vaccine (Inactivated)

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage

Brand Names


Austria: Ixiaro; Belgium: Ixiaro; Bulgaria: Ixiaro; Czech Republic: Ixiaro; Denmark: Ixiaro; Estonia: Ixiaro; Finland: Ixiaro; France: Ixiaro; Germany: Ixiaro; Ireland: Ixiaro; Latvia: Ixiaro; Lithuania: Ixiaro; Luxembourg: Ixiaro; Malta: Ixiaro; Netherlands: Ixiaro; Poland: Ixiaro; Portugal: Ixiaro; Romania: Ixiaro; Slovakia: Ixiaro; Slovenia: Ixiaro; Spain: Ixiaro; Sweden: Ixiaro; UK: Ixiaro.

North America

Canada: JE-Vax; USA: Ixiaro, JE-Vax.


Japan: Japanese Encephalitis Vaccine.

Drug combinations


Pharmacologic Category

Serums, Toxoids, and Vaccines; Vaccines. (ATC-Code: J07BA02).

Mechanism of action

Japanese encephalitis virus vaccine is a lyophilized preparation of inactivated Japanese encephalitis virus which stimulates active immunity to infection by virus.

Therapeutic use

Active immunization against Japanese encephalitis.

Pregnancy and lactiation implications

Pregnant women should only be vaccinated if they are at high risk for exposure. Infection from Japanese encephalitis during the 1^st^ or 2^nd^ trimesters of pregnancy may increase risk of abortion.

Unlabeled use


Hypersensitivity to Japanese encephalitis virus vaccine. Hypersensitivity to any component of vaccine including proteins of rodent or neural origin. Hypersensitivity to thimerosal.

Warnings and precautions

Possible anaphylactoid or hypersensitivity reactions. Severe adverse reactions (generalized urticaria or angioedema) might occur. Use with caution in severe allergies to other medications. Use caution with significant history of urticaria following exposure to insect stings (increased risk of adverse events). Use with caution in severely immunocompromised patients (may have reduced response to vaccination).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart